好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2005 Annual Meeting | Myasthenia Gravis: Diagnosis and Treatment

Friday 04/15/05
09:00 AM - 12:45 PM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
AM Half-Day Course
Henry J. Kaminski, MD, FAAN
Neuromuscular and Clinical Neurophysiology (EMG)
Upon completion:
Participants should be able to recognize the wide range of clinical presentations of myasthenia gravis; select optimal therapy for patients depending on disease severity, comorbid conditions, and individual patient characteristics; and optimize management of patients with myasthenic crisis.

The American Board of Psychiatry and Neurology has reviewed Myasthenia Gravis: Diagnosis and Treatment and has approved this product as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification.
No CME available
Advanced
Practitioner, Fellow, Academician, Resident, Nurse
Event Timeline
09:00 AM - 09:50 AM Ocular Myasthenia: Diagnosis, Treatment and Pathogenesis
Henry J. Kaminski, MD, FAAN
09:50 AM - 10:40 AM Diagnosis of Generalized Myasthenia Gravis
Matthew N. Meriggioli, MD, FAAN
10:40 AM - 11:05 AM Break
11:05 AM - 11:55 AM Treatment of Myasthenia Gravis
Gil I. Wolfe, MD, FAAN
11:55 AM - 12:45 PM Critical Care Management of Myasthenic Crisis
Jose I. Suarez, MD, FAAN
Faculty Disclosures
Henry J. Kaminski, MD, FAAN Dr. Kaminski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Kaminski has received personal compensation in the range of $0-$499 for serving as a Consultant for Cabaletta Bio. The institution of Dr. Kaminski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Kaminski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Canopy Immunotherapeutics. Dr. Kaminski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Curie.bio. Dr. Kaminski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Samsung. Dr. Kaminski has received personal compensation in the range of $0-$499 for serving as a Consultant for Care Constitution. Dr. Kaminski has stock in mimivax. The institution of Dr. Kaminski has received research support from National Institutes of Health. Dr. Kaminski has received publishing royalties from a publication relating to health care.
Matthew N. Meriggioli, MD, FAAN Dr. Meriggioli has received personal compensation for serving as an employee of Novartis Gene Therapies. Dr. Meriggioli has received stock or an ownership interest from Novartis.
Jose I. Suarez, MD, FAAN Dr. Suarez has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Idorsia. Dr. Suarez has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for The Mayo Clinic.
Gil I. Wolfe, MD, FAAN Dr. Wolfe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Wolfe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Wolfe has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for ArgenX. Dr. Wolfe has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB/Ra. Dr. Wolfe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Wolfe has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Cartesian. Dr. Wolfe has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Grifols. The institution of Dr. Wolfe has received research support from UCB/Ra. The institution of Dr. Wolfe has received research support from Immunovant. The institution of Dr. Wolfe has received research support from Roche. Dr. Wolfe has received personal compensation in the range of $0-$499 for serving as a Advisor with FDA Advisory Panel for Cellular, Tissue and Genetic Therapies.